VAXDIGM Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Seoul South Korea

Primary Industry

Biotechnology

About

Based in Seoul, South Korea, and founded in 2021 by Seung-Hoo Kim (CTO), VAXDIGM operates as a biotechnology company that is focused on the research and development of vaccines. In October 2022, VAXDIGM raised seed funding from Korea Tech Incubator for Startups, being selected for Accelerator Investment-Driven Tech Incubator Program. As of October 2022, Kim Seong-jae is the Chief Operating Officer (CEO) of the company. VAXDIGM uses the original technology for rapid vaccine production to develop improved vaccines and future vaccines, including twin-demic (COVID-19 & flu) vaccines. The firm offers cost-effective growth of artificial antigen vaccines using source technology for development and production using microorganisms rather than moth and animal cells. The company plans to use the October 2022 funding to accelerate R&D and technological advancement through non-clinical trials starting at the end of this year.

Current Investors

Korea Tech Incubator for Startup, New Paradigm Investment

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT

Website

www.vaxdigm.com

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.